Wall Street expects a year-over-year increase in earnings on higher revenues when Navidea Biopharma (NAVB) reports results for the quarter ended September 2021. While this widely-known consensus ...

Navidea Biopharmaceuticals, Inc NAVB has been on the move lately as the stock has risen by 29.4% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F ...

Is Navidea Biopharmaceuticals Inc (NYSE:NAVB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of ...

Navidea Biopharmaceuticals (NYSEMKT:NAVB) puts up a pretty substantial top-line miss for Q3. Lymphoseek sales for the period: $144K. NAVB emphasizes a 600% Q/Q increase in unit dose sales and a ...

Short interest in Navidea Biopharmaceuticals Inc (OTC:NAVB) increased during the last reporting period, rising from 394.00 to 466.00. This put -% of the company's publicly available shares short.

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...